Home Daily Stock Opinions and Ratings Theragenics Corp (TGX-N)

Trending stocks today

Morguard Corporation CNHI Industrial Halliburton Co Cenovus Energy Chartwell Retirement Residences Bank of America Chevron Texaco Dycom Industries Tesla Inc Verizon Communications British American Tobacco RenaissanceRe Holdings United Therapeutics Corp. Keg Royalties Income Fund CGI Group (A) Yum China Holdings Inc Brookfield Infrastructure Partners Starbucks Astrazeneca P L C

Theragenics Corp (TGX-N)

NEW AI Investor Insights
2 watching

0.00
0.00 (0.00%) 1d
0
PAST TOP PICK

Theragenics Corp(TGX-N)

06/12/2011
Theragenics Corp
(Top Pick Nov 11/10, Up 27.69%) Got tired of management – salaries were too high. They took on debt.
biotechnology / pharmaceutical
Benj Gallander
$1.660
No
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

03/11/2011
Theragenics Corp
(A Top Pick Nov 11/10. Up 28.57%.)
biotechnology / pharmaceutical
Benj Gallander
$1.600
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

04/10/2011
Theragenics Corp
(Top Pick Nov 11/10, Down 2.30%) out of it personally but fund holds it. Is on their buy list.
biotechnology / pharmaceutical
Benj Gallander
$1.250
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

11/11/2010
Theragenics Corp
Seeds for cancer patients but also do surgical products. Marginally profitable but revenues are up to record levels at about $80 million. Paying down debt. Would like to see a cleaner balance sheet.
biotechnology / pharmaceutical
Benj Gallander
$1.300
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

24/12/2007
Theragenics Corp
Cancer therapy. Revenues have grown. Acquired a $10 million company for $30 million, which was questionable. Fairly clean balance sheet.
biotechnology / pharmaceutical
Benj Gallander
$3.710
Owned
UnlockRating
WEAK BUY

Theragenics Corp(TGX-N)

06/10/2006
Theragenics Corp
Prostate cancer field. Recently expanded into all kinds of other medical devices, including some four cats and dogs. Made some poor acquisitions. Not happy with management.
biotechnology / pharmaceutical
Benj Gallander
$3.070
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

30/01/2006
Theragenics Corp
(A Top Pick Sept 6/05. Up 9.5%.) They have cut out their R&D which will save them a lot of money. Acquired another firm which will increase their revenues. They have a beautiful balance sheet. Still have it on their BUY list.
biotechnology / pharmaceutical
Benj Gallander
$3.480
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

06/09/2005
Theragenics Corp
In the medical products field and treat prostate cancer. Their R&D over the last couple of years has not produced anything. Has a pretty good balance sheet and no debt. BV take a hit because they will be writing off their nuclear research assets. Restructuring and if they just do anything right they will be good as they are dominant in their field.
biotechnology / pharmaceutical
Ben Stadelmann
$3.150
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

12/01/2005
Theragenics Corp
They have an isotope that is a less invasive way of treating prostrate cancer as opposed to surgery. They're dominant in this field. Had difficulty because of insurance coverage issues. Their competition also has treatment methods, so have competition. Losing money because of more going into R & D. New marketing may help.
biotechnology / pharmaceutical
Ben Stadelmann
$3.970
Owned
UnlockRating
PAST TOP PICK

Theragenics Corp(TGX-N)

09/11/2004
Theragenics Corp
(A Top Pick June 14/04. Down 12%.) Have about $30 million in revenues. Operate in the prostrate cancer area which is a growing field. Still on their buy list, but wait until December for tax loss selling. No debt. Good management.
biotechnology / pharmaceutical
Benj Gallander
$3.900
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

16/09/2004
Theragenics Corp
A demographics play in treatment of prostrate cancer. Dominant in their field. Midicare payment problem seems to be getting worked out. R&D is looking for other cancer treatments.
biotechnology / pharmaceutical
Ben Stadelmann
$3.740
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

21/07/2004
Theragenics Corp
biotechnology / pharmaceutical
Benj Gallander
$4.360
Owned
UnlockRating
TOP PICK

Theragenics Corp(TGX-N)

16/07/2004
Theragenics Corp
Had revenues over $50 million and stock price was over $30. Revenues then dropped to $30 million. Prostate cancer continues to grow demographically and they have a proven product for this. A lot of competition. No long-term debt.
biotechnology / pharmaceutical
Benj Gallander
$4.370
Owned
UnlockRating
Showing 1 to 13 of 13 entries
  • «
  • ‹
  • 1
  • ›
  • »

Theragenics Corp(TGX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Theragenics Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Theragenics Corp(TGX-N) Frequently Asked Questions

What is Theragenics Corp stock symbol?

Theragenics Corp is a OTC stock, trading under the symbol TGX-N on the (). It is usually referred to as or TGX-N

Is Theragenics Corp a buy or a sell?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

Is Theragenics Corp a good investment or a top pick?

Theragenics Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Theragenics Corp.

Why is Theragenics Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Theragenics Corp worth watching?

In the last year, there was no coverage of Theragenics Corp published on Stockchase.

What is Theragenics Corp stock price?

On , Theragenics Corp (TGX-N) stock closed at a price of $.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

SMCI-QSuper Micro Computer
Super Micro Computer
$714.04
-214.44 (-42.92%)
PNG-XKraken Robotics Inc.
Kraken Robotics Inc.
$0.96
-0.04 (-4.35%)
NVDA-QNVIDIA Corporation
NVIDIA Corporation
$762.01
-84.70 (-12.51%)
META-QMeta Platforms, Inc.
Meta Platforms, Inc.
$480.97
-20.83 (-4.53%)
NKE-NNike Inc
Nike Inc
$94.53
-1.21 (-1.30%)
Advertising

Today's Top Picks

AZN-NAstrazeneca P L C
Astrazeneca P L C
$68.56
0.20 (0.29%)
SBUX-QStarbucks
Starbucks
$87.60
0.45 (0.51%)
BIP.UN-TBrookfield Infrastructure Partners
Brookfield Infrastructure Partners
$37.41
1.15 (2.98%)
YUMC-NYum China Holdings Inc
Yum China Holdings Inc
$37.10
-0.12 (-0.32%)
GIB.A-TCGI Group (A)
CGI Group (A)
$142.99
-0.12 (-0.08%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

PYPL-QPayPal Holdings Inc.
PayPal Holdings Inc.
$62.31
0.21 (0.34%)
LLY-NEli Lilly & Co.
Eli Lilly & Co.
$726.31
-19.64 (-2.78%)
TSLA-QTesla Inc
Tesla Inc
$147.01
-2.92 (-2.03%)
WFC-NWells Fargo
Wells Fargo
$60.35
1.61 (2.60%)
EBAY-QeBay Inc
eBay Inc
$50.38
0.43 (0.85%)

Most Recent Experts

Stockchase

Stockchase Insights

5i Research

Cramer

Jim Cramer - Mad Money

CNBC

Hakes

Michael Hakes - CFA, MBA

Murray Wealth Group

Blumas

Chris Blumas

at Raymond James Investment Counsel Ltd.

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.